EU, Health Canada Confirm Regulatory Cooperation

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

On April 2, the Health Products and Food Branch of Health Canada and EU (consisting of the European Commission [EC] and European Medicines Agency [EMEA]) released "Implementation Plan for Regulatory Cooperation on Medicinal Products."

On Apr. 2, 2009, the Health Products and Food Branch of Health Canada and European Union (consisting of the European Commission [EC] and European Medicines Agency [EMEA]) released “Implementation Plan for Regulatory Cooperation on Medicinal Products.” The document describes the process of information and document exchange between both organizations as well as the process for monitoring the implementation of the plan. The agreement follows a confidential Exchange of Letters signed by both parties in December 2007.

The implementation plan covers information relating to regulations, legislation under development, draft guidance documents, and nonpublic information about pharmaceuticals and human biologics under review in Canada and the European Union.

According to the implementation plan, EMEA and Health Canada will continue to cooperate in the development of an “exchange and visit program” (exchange of staff members between each organization) as well as an exchange of documents (both “routine” as agreed upon previously and “ad-hoc”).

To implement the plan, a coordination committee will be formed consisting of members from the EC, EMEA, and Health Canada. The committee will conduct annual evaluations and handle “organizational and operational aspects.” 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes